IGC Pharma

IGC Pharma Current Assets

The Current Assets of IGC Pharma (IGC) as of Nov 12, 2026 is 1.11 M USD. In the previous year, Current Assets was 2.90 M USD — a change of -61.67% (lower).

Current Assets

1.11 MUSD

YoY

-61.67%

Last updated:

Current Assets of IGC Pharma is 2026 1.11 M USD. Current Assets of IGC Pharma was 2025 2.90 M USD. It decreases by -61.67% lower compared to the previous year.

The IGC Pharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
26.72 M USD
Jan 1, 2020
17.75 M USD
Jan 1, 2021
25.26 M USD
Jan 1, 2022
15.11 M USD
Jan 1, 2023
6.47 M USD
Jan 1, 2024
3.70 M USD
Jan 1, 2025
2.90 M USD
Jan 1, 2026
1.11 M USD
The IGC Pharma Current Assets history
YEARCurrent AssetsYoY
1.11 MUSD-61.67%
2.90 MUSD-21.84%
3.70 MUSD-42.69%
6.47 MUSD-57.23%
15.11 MUSD-40.17%
25.26 MUSD+42.29%
17.75 MUSD-33.55%
26.72 MUSD+818.72%
2.91 MUSD-18.73%
3.58 MUSD-6.79%
3.84 MUSD-14.19%
4.47 MUSD+18.93%
3.76 MUSD+47.06%
2.56 MUSD-50.97%
5.22 MUSD-20.25%
6.54 MUSD-41.08%
11.10 MUSD-43.05%
19.50 MUSD-43.10%
34.27 MUSD-49.14%
67.39 MUSD+2.25%
65.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IGC Pharma Stock analysis

What does IGC Pharma do? India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IGC Pharma stock

Current Assets of IGC Pharma is 1.11 M USD in 2026.

Current Assets of IGC Pharma changed from 2.90 M USD to 1.11 M USD, representing a -61.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets IGC Pharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's IGC Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IGC Pharma

All Key Metrics — IGC Pharma